86 related articles for article (PubMed ID: 9708511)
1. Locally increased uptake of fluorine-18-fluorodeoxyglucose after intracavitary administration of iodine-131-labeled antibody for primary brain tumors.
Marriott CJ; Thorstad W; Akabani G; Brown MT; McLendon RE; Hanson MW; Coleman RE
J Nucl Med; 1998 Aug; 39(8):1376-80. PubMed ID: 9708511
[TBL] [Abstract][Full Text] [Related]
2. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors.
Weber W; Bartenstein P; Gross MW; Kinzel D; Daschner H; Feldmann HJ; Reidel G; Ziegler SI; Lumenta C; Molls M; Schwaiger M
J Nucl Med; 1997 May; 38(5):802-8. PubMed ID: 9170450
[TBL] [Abstract][Full Text] [Related]
3. [Initial experiences with adjuvant locoregional radioimmunotherapy using 131I-labeled monoclonal antibodies against tenascin (BC-4) for treatment of glioma (WHO III and IV)].
Pöpperl G; Götz C; Gildehaus FJ; Yousry TA; Reulen HJ; Hahn K; Tatsch K
Nuklearmedizin; 2002 Jun; 41(3):120-8. PubMed ID: 12109031
[TBL] [Abstract][Full Text] [Related]
4. Independent thallium-201 accumulation and fluorine-18-fluorodeoxyglucose metabolism in glioma.
Oriuchi N; Tomiyoshi K; Inoue T; Ahmad K; Sarwar M; Tokunaga M; Suzuki H; Watanabe N; Hirano T; Horikoshi S; Shibasaki T; Tamura M; Endo K
J Nucl Med; 1996 Mar; 37(3):457-62. PubMed ID: 8772644
[TBL] [Abstract][Full Text] [Related]
5. Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II study.
Akabani G; Reardon DA; Coleman RE; Wong TZ; Metzler SD; Bowsher JE; Barboriak DP; Provenzale JM; Greer KL; DeLong D; Friedman HS; Friedman AH; Zhao XG; Pegram CN; McLendon RE; Bigner DD; Zalutsky MR
J Nucl Med; 2005 Jun; 46(6):1042-51. PubMed ID: 15937318
[TBL] [Abstract][Full Text] [Related]
6. Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas.
Roelcke U; Blasberg RG; von Ammon K; Hofer S; Vontobel P; Maguire RP; Radü EW; Herrmann R; Leenders KL
J Nucl Med; 1998 May; 39(5):879-84. PubMed ID: 9591593
[TBL] [Abstract][Full Text] [Related]
7. PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome.
Valk PE; Budinger TF; Levin VA; Silver P; Gutin PH; Doyle WK
J Neurosurg; 1988 Dec; 69(6):830-8. PubMed ID: 2848111
[TBL] [Abstract][Full Text] [Related]
8. Preoperative evaluation of 54 gliomas by PET with fluorine-18-fluorodeoxyglucose and/or carbon-11-methionine.
Kaschten B; Stevenaert A; Sadzot B; Deprez M; Degueldre C; Del Fiore G; Luxen A; Reznik M
J Nucl Med; 1998 May; 39(5):778-85. PubMed ID: 9591574
[TBL] [Abstract][Full Text] [Related]
9. Dosimetry of 131I-labeled 81C6 monoclonal antibody administered into surgically created resection cavities in patients with malignant brain tumors.
Akabani G; Reist CJ; Cokgor I; Friedman AH; Friedman HS; Coleman RE; Zhao XG; Bigner DD; Zalutsky MR
J Nucl Med; 1999 Apr; 40(4):631-8. PubMed ID: 10210222
[TBL] [Abstract][Full Text] [Related]
10. Glucose metabolism in human malignant gliomas measured quantitatively with PET, 1-[C-11]glucose and FDG: analysis of the FDG lumped constant.
Spence AM; Muzi M; Graham MM; O'Sullivan F; Krohn KA; Link JM; Lewellen TK; Lewellen B; Freeman SD; Berger MS; Ojemann GA
J Nucl Med; 1998 Mar; 39(3):440-8. PubMed ID: 9529289
[TBL] [Abstract][Full Text] [Related]
11. Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results.
Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; Herndon JE; McLendon RE; Pegram CN; Provenzale JM; Quinn JA; Rich JN; Vredenburgh JJ; Desjardins A; Gururangan S; Badruddoja M; Dowell JM; Wong TZ; Zhao XG; Zalutsky MR; Bigner DD
J Clin Oncol; 2006 Jan; 24(1):115-22. PubMed ID: 16382120
[TBL] [Abstract][Full Text] [Related]
12. Hyperacute changes in glucose metabolism of brain tumors after stereotactic radiosurgery: a PET study.
Maruyama I; Sadato N; Waki A; Tsuchida T; Yoshida M; Fujibayashi Y; Ishii Y; Kubota T; Yonekura Y
J Nucl Med; 1999 Jul; 40(7):1085-90. PubMed ID: 10405124
[TBL] [Abstract][Full Text] [Related]
13. 18F alpha-methyl tyrosine PET studies in patients with brain tumors.
Inoue T; Shibasaki T; Oriuchi N; Aoyagi K; Tomiyoshi K; Amano S; Mikuni M; Ida I; Aoki J; Endo K
J Nucl Med; 1999 Mar; 40(3):399-405. PubMed ID: 10086702
[TBL] [Abstract][Full Text] [Related]
14. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG PET.
Jones DN; McCowage GB; Sostman HD; Brizel DM; Layfield L; Charles HC; Dewhirst MW; Prescott DM; Friedman HS; Harrelson JM; Scully SP; Coleman RE
J Nucl Med; 1996 Sep; 37(9):1438-44. PubMed ID: 8790188
[TBL] [Abstract][Full Text] [Related]
15. 2-[C-11]thymidine imaging of malignant brain tumors.
Eary JF; Mankoff DA; Spence AM; Berger MS; Olshen A; Link JM; O'Sullivan F; Krohn KA
Cancer Res; 1999 Feb; 59(3):615-21. PubMed ID: 9973209
[TBL] [Abstract][Full Text] [Related]
16. Use of [18F]fluorodeoxyglucose positron emission tomography in patients with primary malignant brain tumors.
Janus TJ; Kim EE; Tilbury R; Bruner JM; Yung WK
Ann Neurol; 1993 May; 33(5):540-8. PubMed ID: 8498831
[TBL] [Abstract][Full Text] [Related]
17. Regression of advanced refractory ovarian cancer treated with iodine-131-labeled anti-CEA monoclonal antibody.
Juweid M; Sharkey RM; Alavi A; Swayne LC; Herskovic T; Hanley D; Rubin AD; Pereira M; Goldenberg DM
J Nucl Med; 1997 Feb; 38(2):257-60. PubMed ID: 9025751
[TBL] [Abstract][Full Text] [Related]
18. Differentiation between recurrent brain tumour and post-radiation necrosis: the value of 201Tl SPET versus 18F-FDG PET using a dual-headed coincidence camera--a pilot study.
Stokkel M; Stevens H; Taphoorn M; Van Rijk P
Nucl Med Commun; 1999 May; 20(5):411-7. PubMed ID: 10404525
[TBL] [Abstract][Full Text] [Related]
19. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
20. Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy.
Goldman S; Levivier M; Pirotte B; Brucher JM; Wikler D; Damhaut P; Dethy S; Brotchi J; Hildebrand J
J Nucl Med; 1997 Sep; 38(9):1459-62. PubMed ID: 9293808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
